Visit our community blood centers in Illinois, Indiana, Michigan and Wisconsin.
About Us Careers Customer Service Diversity Events Newsroom
St. Jude Children’s Research Hospital
PhD, University of Tennessee Medical School, 1996
Wen lab has two different, but interconnected research focuses. One focus of the Wen lab is aimed at understanding the signaling pathways that govern proper B and T cell activation and communications and how aberrant signaling in T and B cells will lead to human diseases. The lab has studied the mechanisms by which molecules in antigen receptor signaling pathways such as: phospholipase C gamma (PLCg), B-cell lymphoma 10 (Bcl10), and molecules in cytokine signaling pathways, including Grb2-associated binding (Gab) proteins, control and modulate T and B cell development and activation and how aberrant functions of these molecules lead to lymphopenia and autoimmunity.
Another major focus of the Wen lab is understanding the interplay between immune systems and coagulation systems in healthy and disease states. Currently, the lab is studying how antibodies regulate the function of platelets and other cells involved in the coagulation system and the prevalence, ontogeny, and activation of the host B cells that make such antibodies in healthy people and patients with heparin-induced thrombocytopenia and thrombosis (HIT) and COVID-19. Studies will be performed in both human and mouse systems using techniques of biochemistry, cell biology, molecular biology, and bioinformatics with the goal of understanding the molecular pathogenesis underlying antibody mediated thrombotic complications in HIT and COVID-19 and developing new diagnostic and therapeutic tools for these conditions.
R01 HL148120 (PI), "Molecular Basis of Humoral Immune Response in Heparin-Induced Thrombocytopenia" 2019-2023
R01 AI083636-06 (PI: Salomon), "Phosphoproteomic Analysis of Feedback Networks in T Cell Signaling" 2017-2022
R01 HL130724 (PI: Wang), "B Cell Responses in Heparin-Induced Thrombocytopenia" 2021-2025
Ziegler Family Innovation Award (PI), "Development of RBD-specific Platelet-activating Antibodies in COVID-19 Patients" 2021-2022
ACTIV-4 Mechanistic Studies (PI: Kreuziger) "Antibody Mediated Thromboinflammation in COVID-19" 2021-2022
Sr. Research Associate
Click here for a complete list of publications.